Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies
<a href="https://pixabay.com/users/geralt/">geralt</a> / Pixabay

Initial Trial Data Looks Promising for a Potential Treatment for Rare Epilepsies

According to a story from sectorpublishingintelligence.co.uk, the drug company Ovid Therapeutics Inc. has recently announced that the early data from its phase 2 clinical trial is mostly encouraging. This clinical…

Continue Reading
Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

Two Phase 2 Clinical Studies of a Drug for Rare Epilepsies Have Been Initiated

Two Phase 2 clinical trials called ‘Elektra’ and ‘Arcade’ have been initiated. They will investigate the drug OV935/TAK-935 as a potential treatment for paediatric patients with rare epilepsies. For more…

Continue Reading
Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug
<a href="https://pixabay.com/users/stevepb/">stevepb</a> / Pixabay

Takeda and Ovid Have Provided an Update on the Clinical Development Program for an Investigational Anti-Epileptic Drug

  Takeda Pharmaceutical Company Limited and Ovid Therapeutics have released an overview of the clinical development program for TAK-935/OV935, an investigational drug that is being developed as a potential anti-epileptic…

Continue Reading
  • 1
  • 2
Close Menu